Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;4(4):226-30.
doi: 10.1002/psp4.33. Epub 2015 Apr 17.

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

C Wagner  1 , P Zhao  1 , Y Pan  2 , V Hsu  1 , J Grillo  1 , S M Huang  1 , V Sinha  1
Affiliations

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

C Wagner et al. CPT Pharmacometrics Syst Pharmacol. 2015 Apr.

Abstract

The US Food and Drug Administration (FDA) public workshop, entitled "Application of Physiologically-based Pharmacokinetic (PBPK) Modeling to Support Dose Selection focused on the role of PBPK in drug development and regulation. Representatives from industry, academia, and regulatory agencies discussed the issues within plenary and panel discussions. This report summarizes the discussions and provides current perspectives on the application of PBPK in different areas, including its utility, predictive performance, and reporting for regulatory submissions.

PubMed Disclaimer

References

    1. Federal Register: FDA Public Workshop “Application of Physiologically-Based Pharmacokinetic Modeling to Support Dose Selection.” < https://www.federalregister.gov/articles/2014/02/11/2014-02883/applicati... > (2014) - PMC - PubMed
    1. 2014 FDA Public Workshop: Application of Physiologically-Based Pharmacokinetic Modeling to Support Dose Selection. < http://www.fda.gov/Drugs/NewsEvents/ucm387698.htm > (2014). Accessed on 27 October 2014.
    1. Wagner C, et al. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin. Pharmacokinet. 2015;54:117–127. ) - PubMed
    1. Vieira MD, et al. PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. Clin. Pharmacol. Ther. 2014;95:550–557. ) - PubMed
    1. Ibrutinib Clinical Pharmacology and Biopharmaceutics Review. < http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000Cl... > (2013). Accessed on 2 February 2014.